In Brief: FDA reform
This article was originally published in The Gray Sheet
Executive Summary
FDA reform: House Commerce/Health Subcommittee slated to mark up FDA reform legislation Aug. 1, one day before Congress is scheduled to begin its August recess. The mark-up is expected to cover bills on medical devices (HR 3201) and drugs/biologics (HR 3199), revised drafts of which were released July 10 ("The Gray Sheet" July 15, p. 3). Mark-up in the full Commerce Committee has not been scheduled...
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.